GSK PLC-SPON ADR (GSK) Fundamental Analysis & Valuation

NYSE:GSK • US37733W2044

Current stock price

54.305 USD
-0.13 (-0.25%)
Last:

This GSK fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

9

1. GSK Profitability Analysis

1.1 Basic Checks

  • In the past year GSK was profitable.
  • GSK had a positive operating cash flow in the past year.
  • GSK had positive earnings in each of the past 5 years.
  • In the past 5 years GSK always reported a positive cash flow from operatings.
GSK Yearly Net Income VS EBIT VS OCF VS FCFGSK Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5B 10B

1.2 Ratios

  • With an excellent Return On Assets value of 9.35%, GSK belongs to the best of the industry, outperforming 90.05% of the companies in the same industry.
  • Looking at the Return On Equity, with a value of 34.90%, GSK belongs to the top of the industry, outperforming 95.29% of the companies in the same industry.
  • Looking at the Return On Invested Capital, with a value of 19.80%, GSK belongs to the top of the industry, outperforming 96.86% of the companies in the same industry.
  • GSK had an Average Return On Invested Capital over the past 3 years of 18.70%. This is significantly above the industry average of 13.10%.
  • The 3 year average ROIC (18.70%) for GSK is below the current ROIC(19.80%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 9.35%
ROE 34.9%
ROIC 19.8%
ROA(3y)7.34%
ROA(5y)10.49%
ROE(3y)30.22%
ROE(5y)52.18%
ROIC(3y)18.7%
ROIC(5y)16.61%
GSK Yearly ROA, ROE, ROICGSK Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -500 -1K -1.5K -2K

1.3 Margins

  • GSK has a better Profit Margin (17.50%) than 91.10% of its industry peers.
  • GSK's Profit Margin has declined in the last couple of years.
  • The Operating Margin of GSK (28.36%) is better than 93.72% of its industry peers.
  • GSK's Operating Margin has improved in the last couple of years.
  • GSK's Gross Margin of 72.67% is amongst the best of the industry. GSK outperforms 80.63% of its industry peers.
  • In the last couple of years the Gross Margin of GSK has remained more or less at the same level.
Industry RankSector Rank
OM 28.36%
PM (TTM) 17.5%
GM 72.67%
OM growth 3Y0.87%
OM growth 5Y3.61%
PM growth 3Y-29.99%
PM growth 5Y-5.81%
GM growth 3Y0.89%
GM growth 5Y0.87%
GSK Yearly Profit, Operating, Gross MarginsGSK Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20 40 60

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. GSK Health Analysis

2.1 Basic Checks

  • GSK has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
  • GSK has less shares outstanding than it did 1 year ago.
  • GSK has more shares outstanding than it did 5 years ago.
  • GSK has a worse debt/assets ratio than last year.
GSK Yearly Shares OutstandingGSK Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B 2B
GSK Yearly Total Debt VS Total AssetsGSK Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20B 40B 60B 80B

2.2 Solvency

  • An Altman-Z score of 2.30 indicates that GSK is not a great score, but indicates only limited risk for bankruptcy at the moment.
  • GSK's Altman-Z score of 2.30 is in line compared to the rest of the industry. GSK outperforms 59.69% of its industry peers.
  • GSK has a debt to FCF ratio of 3.73. This is a good value and a sign of high solvency as GSK would need 3.73 years to pay back of all of its debts.
  • With an excellent Debt to FCF ratio value of 3.73, GSK belongs to the best of the industry, outperforming 87.96% of the companies in the same industry.
  • A Debt/Equity ratio of 0.90 indicates that GSK is somewhat dependend on debt financing.
  • The Debt to Equity ratio of GSK (0.90) is worse than 75.92% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.9
Debt/FCF 3.73
Altman-Z 2.3
ROIC/WACC2.29
WACC8.65%
GSK Yearly LT Debt VS Equity VS FCFGSK Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 5B 10B 15B 20B

2.3 Liquidity

  • A Current Ratio of 0.82 indicates that GSK may have some problems paying its short term obligations.
  • GSK has a Current ratio of 0.82. This is amonst the worse of the industry: GSK underperforms 90.05% of its industry peers.
  • GSK has a Quick Ratio of 0.82. This is a bad value and indicates that GSK is not financially healthy enough and could expect problems in meeting its short term obligations.
  • GSK has a worse Quick ratio (0.54) than 91.62% of its industry peers.
Industry RankSector Rank
Current Ratio 0.82
Quick Ratio 0.54
GSK Yearly Current Assets VS Current LiabilitesGSK Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5B 10B 15B 20B 25B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. GSK Growth Analysis

3.1 Past

  • The Earnings Per Share has been growing slightly by 7.84% over the past year.
  • GSK shows a small growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 3.55% yearly.
  • The Revenue has been growing slightly by 4.11% in the past year.
  • The Revenue has been growing slightly by 6.05% on average over the past years.
EPS 1Y (TTM)7.84%
EPS 3Y5.13%
EPS 5Y3.55%
EPS Q2Q%9.91%
Revenue 1Y (TTM)4.11%
Revenue growth 3Y3.66%
Revenue growth 5Y6.05%
Sales Q2Q%6.17%

3.2 Future

  • The Earnings Per Share is expected to grow by 4.88% on average over the next years.
  • The Revenue is expected to grow by 3.07% on average over the next years.
EPS Next Y8.2%
EPS Next 2Y8.45%
EPS Next 3Y6.65%
EPS Next 5Y4.88%
Revenue Next Year4.39%
Revenue Next 2Y4.29%
Revenue Next 3Y3.85%
Revenue Next 5Y3.07%

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
  • The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
GSK Yearly Revenue VS EstimatesGSK Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 10B 20B 30B
GSK Yearly EPS VS EstimatesGSK Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 1 2 3 4

More info and screens

Find the best growth stocksShow best growing peers

8

4. GSK Valuation Analysis

4.1 Price/Earnings Ratio

  • With a Price/Earnings ratio of 11.46, the valuation of GSK can be described as very reasonable.
  • Based on the Price/Earnings ratio, GSK is valued cheaper than 89.01% of the companies in the same industry.
  • GSK is valuated cheaply when we compare the Price/Earnings ratio to 27.42, which is the current average of the S&P500 Index.
  • GSK is valuated reasonably with a Price/Forward Earnings ratio of 10.59.
  • GSK's Price/Forward Earnings ratio is rather cheap when compared to the industry. GSK is cheaper than 86.91% of the companies in the same industry.
  • The average S&P500 Price/Forward Earnings ratio is at 22.29. GSK is valued rather cheaply when compared to this.
Industry RankSector Rank
PE 11.46
Fwd PE 10.59
GSK Price Earnings VS Forward Price EarningsGSK Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

  • GSK's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. GSK is cheaper than 90.58% of the companies in the same industry.
  • Based on the Price/Free Cash Flow ratio, GSK is valued cheaper than 85.86% of the companies in the same industry.
Industry RankSector Rank
P/FCF 16.9
EV/EBITDA 8.2
GSK Per share dataGSK EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10 15 20

4.3 Compensation for Growth

  • The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
  • The excellent profitability rating of GSK may justify a higher PE ratio.
PEG (NY)1.4
PEG (5Y)3.23
EPS Next 2Y8.45%
EPS Next 3Y6.65%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

5

5. GSK Dividend Analysis

5.1 Amount

  • With a Yearly Dividend Yield of 3.37%, GSK has a reasonable but not impressive dividend return.
  • GSK's Dividend Yield is rather good when compared to the industry average which is at 0.73. GSK pays more dividend than 95.29% of the companies in the same industry.
  • Compared to an average S&P500 Dividend Yield of 1.81, GSK pays a better dividend.
Industry RankSector Rank
Dividend Yield 3.37%

5.2 History

  • The dividend of GSK decreases each year by -8.93%.
  • GSK has been paying a dividend for at least 10 years, so it has a reliable track record.
  • The dividend of GSK decreased in the last 3 years.
Dividend Growth(5Y)-8.93%
Div Incr Years2
Div Non Decr Years2
GSK Yearly Dividends per shareGSK Yearly Dividends per shareYearly Dividends per share 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 0.5 1 1.5 2

5.3 Sustainability

  • GSK pays out 44.86% of its income as dividend. This is a bit on the high side, but may be sustainable.
DP44.86%
EPS Next 2Y8.45%
EPS Next 3Y6.65%
GSK Yearly Income VS Free CF VS DividendGSK Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5B 10B
GSK Dividend Payout.GSK Dividend Payout, showing the Payout Ratio.GSK Dividend Payout.PayoutRetained Earnings

More info and screens

Find the best dividend stocksShow peers with best dividend

GSK Fundamentals: All Metrics, Ratios and Statistics

GSK PLC-SPON ADR

NYSE:GSK (4/27/2026, 2:28:49 PM)

54.305

-0.13 (-0.25%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-04
Earnings (Next)04-29
Inst Owners46.1%
Inst Owner Change-0.14%
Ins Owners0.13%
Ins Owner ChangeN/A
Market Cap108.47B
Revenue(TTM)32.67B
Net Income(TTM)5.72B
Analysts68.75
Price Target56.54 (4.12%)
Short Float %0.82%
Short Ratio2.93
Dividend
Industry RankSector Rank
Dividend Yield 3.37%
Yearly Dividend1.72
Dividend Growth(5Y)-8.93%
DP44.86%
Div Incr Years2
Div Non Decr Years2
Ex-Date02-20
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)10.74%
Min EPS beat(2)8.69%
Max EPS beat(2)12.8%
EPS beat(4)4
Avg EPS beat(4)9.75%
Min EPS beat(4)7.67%
Max EPS beat(4)12.8%
EPS beat(8)8
Avg EPS beat(8)11.8%
EPS beat(12)11
Avg EPS beat(12)9.51%
EPS beat(16)15
Avg EPS beat(16)10.21%
Revenue beat(2)0
Avg Revenue beat(2)-0.76%
Min Revenue beat(2)-1.24%
Max Revenue beat(2)-0.28%
Revenue beat(4)0
Avg Revenue beat(4)-0.79%
Min Revenue beat(4)-1.6%
Max Revenue beat(4)-0.04%
Revenue beat(8)3
Avg Revenue beat(8)-0.16%
Revenue beat(12)7
Avg Revenue beat(12)1.25%
Revenue beat(16)9
Avg Revenue beat(16)-0.18%
PT rev (1m)3.26%
PT rev (3m)11.89%
EPS NQ rev (1m)1.41%
EPS NQ rev (3m)-1.69%
EPS NY rev (1m)-0.15%
EPS NY rev (3m)-0.11%
Revenue NQ rev (1m)-0.75%
Revenue NQ rev (3m)-1.57%
Revenue NY rev (1m)0.17%
Revenue NY rev (3m)-0.67%
Valuation
Industry RankSector Rank
PE 11.46
Fwd PE 10.59
P/S 2.46
P/FCF 16.9
P/OCF 10.39
P/B 4.91
P/tB N/A
EV/EBITDA 8.2
EPS(TTM)4.74
EY8.73%
EPS(NY)5.13
Fwd EY9.44%
FCF(TTM)3.21
FCFY5.92%
OCF(TTM)5.23
OCFY9.63%
SpS22.07
BVpS11.06
TBVpS-4.99
PEG (NY)1.4
PEG (5Y)3.23
Graham Number34.3486 (-36.75%)
Profitability
Industry RankSector Rank
ROA 9.35%
ROE 34.9%
ROCE 23.32%
ROIC 19.8%
ROICexc 21.66%
ROICexgc 62.66%
OM 28.36%
PM (TTM) 17.5%
GM 72.67%
FCFM 14.56%
ROA(3y)7.34%
ROA(5y)10.49%
ROE(3y)30.22%
ROE(5y)52.18%
ROIC(3y)18.7%
ROIC(5y)16.61%
ROICexc(3y)20.78%
ROICexc(5y)19.73%
ROICexgc(3y)57.08%
ROICexgc(5y)71.93%
ROCE(3y)22.62%
ROCE(5y)20.15%
ROICexgc growth 3Y-21.48%
ROICexgc growth 5Y-6.47%
ROICexc growth 3Y-6.23%
ROICexc growth 5Y14.55%
OM growth 3Y0.87%
OM growth 5Y3.61%
PM growth 3Y-29.99%
PM growth 5Y-5.81%
GM growth 3Y0.89%
GM growth 5Y0.87%
F-Score9
Asset Turnover0.53
Health
Industry RankSector Rank
Debt/Equity 0.9
Debt/FCF 3.73
Debt/EBITDA 1.27
Cap/Depr 129%
Cap/Sales 9.14%
Interest Coverage 13.64
Cash Conversion 66.86%
Profit Quality 83.21%
Current Ratio 0.82
Quick Ratio 0.54
Altman-Z 2.3
F-Score9
WACC8.65%
ROIC/WACC2.29
Cap/Depr(3y)116.02%
Cap/Depr(5y)115.31%
Cap/Sales(3y)8.79%
Cap/Sales(5y)9.19%
Profit Quality(3y)103.9%
Profit Quality(5y)92.12%
High Growth Momentum
Growth
EPS 1Y (TTM)7.84%
EPS 3Y5.13%
EPS 5Y3.55%
EPS Q2Q%9.91%
EPS Next Y8.2%
EPS Next 2Y8.45%
EPS Next 3Y6.65%
EPS Next 5Y4.88%
Revenue 1Y (TTM)4.11%
Revenue growth 3Y3.66%
Revenue growth 5Y6.05%
Sales Q2Q%6.17%
Revenue Next Year4.39%
Revenue Next 2Y4.29%
Revenue Next 3Y3.85%
Revenue Next 5Y3.07%
EBIT growth 1Y18.74%
EBIT growth 3Y4.57%
EBIT growth 5Y9.87%
EBIT Next Year28.9%
EBIT Next 3Y11.66%
EBIT Next 5Y7.11%
FCF growth 1Y33.15%
FCF growth 3Y-2.59%
FCF growth 5Y-5.17%
OCF growth 1Y18.11%
OCF growth 3Y1.5%
OCF growth 5Y-1.72%

GSK PLC-SPON ADR / GSK Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for GSK PLC-SPON ADR?

ChartMill assigns a fundamental rating of 6 / 10 to GSK.


What is the valuation status of GSK PLC-SPON ADR (GSK) stock?

ChartMill assigns a valuation rating of 8 / 10 to GSK PLC-SPON ADR (GSK). This can be considered as Undervalued.


Can you provide the profitability details for GSK PLC-SPON ADR?

GSK PLC-SPON ADR (GSK) has a profitability rating of 9 / 10.


What is the valuation of GSK PLC-SPON ADR based on its PE and PB ratios?

The Price/Earnings (PE) ratio for GSK PLC-SPON ADR (GSK) is 11.46 and the Price/Book (PB) ratio is 4.91.


Can you provide the expected EPS growth for GSK stock?

The Earnings per Share (EPS) of GSK PLC-SPON ADR (GSK) is expected to grow by 8.2% in the next year.